Loading
NASDAQHealthcareBiotechnology
Latest quote
$60.41
−$1.07 · -1.74%
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Regular session
$60.41
−$1.07 · -1.74%
Regular session · ET · Market data may be delayed.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Day range
Current $60.41
52-week range
Current $60.41
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
71
Undervalued
Sentiment
47
Mixed
Risk
44
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Day range
Current $60.41
52-week range
Current $60.41
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 829.45M USD | 3.55M USD | 240.74M USD | 243.23M USD | 138.29M USD |
| Cost of goods sold | — | 18.6M USD | 12.49M USD | 10.42M USD | — |
| Gross profit | 829.45M USD | −15.04M USD | 228.24M USD | 232.81M USD | 138.29M USD |
| Research and development | 607.16M USD | 489.22M USD | 342.31M USD | 288.5M USD | 206.34M USD |
| Selling, general, and administrative | 121.92M USD | 96.82M USD | 90.93M USD | 124.43M USD | 80.98M USD |
| Operating expenses | 731.1M USD | 586.04M USD | 433.24M USD | 411.32M USD | 287.32M USD |
| Interest income | 37.29M USD | 22.72M USD | 15.3M USD | 5.03M USD | 6.12M USD |
| Interest expense | 89.36M USD | 32.35M USD | 18.33M USD | — | — |
| Depreciation and amortization | 23.93M USD | 18.6M USD | 12.49M USD | 10.42M USD | 8.27M USD |
| Operating income | 98.35M USD | −601.08M USD | −205M USD | −178.51M USD | −149.04M USD |
| Net income | −1.63M USD | −599.49M USD | −205.28M USD | −176.06M USD | −140.85M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$100.63
66.58% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 17, 2011 | 1:10 | — | — |
Stock split | Jan 15, 2004 | 1:65 | — | — |
Effective Nov 17, 2011
1:10
Effective Jan 15, 2004
1:65
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI350.6M0.01%2.3T USD0.03%$379.71-0.35%
iShares Core S&P Mid-Cap ETFIJH311.58M0.26%124.07B USD0.05%$72.49-0.37%
Vanguard Morningstar Small-Cap ETFVB253.69M0.14%185.3B USD0.03%$285.58-0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK145.59M0.32%44.7B USD0.05%$339.84-0.70%
Vanguard Extended Market ETFVXF134.83M0.14%95.4B USD0.05%$232.13-0.58%
State Street SPDR S&P Biotech ETFXBI115.27M1.12%10.08B USD0.35%$148.13-1.40%
Invesco S&P MidCap Momentum ETFXMMO110.94M1.53%7.25B USD0.34%$147.15-0.79%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY64.37M0.25%25.98B USD0.23%$661.06-0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Core S&P Mid-Cap ETFIJHVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIInvesco S&P MidCap Momentum ETFXMMOState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
